|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000166833 |
Summary for NAV2 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000166833 | Gene symbol | NAV2 |
| Gene name | neuron navigator 2 | |
| HGNC | 15997 | |
| Entrez ID | 89797 | |
| Gene type | protein_coding | |
| Synonyms | NAV2|FLJ10633|FLJ11030|HELAD1|KIAA1419|POMFIL2|RAINB1|FLJ23707 | |
| UniProtAcc | Q8IVL1 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for NAV2 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| NAV2 | 2.07e+03 | -1.55e+00 | 1.97e-01 | -7.87e+00 | 3.55e-15 | 4.24e-14 | KIRP |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| NAV2 | 3.24e+03 | -1.31e+00 | 1.15e-01 | -1.14e+01 | 5.39e-30 | 2.74e-29 | BRCA |
Top |
Sex-biased somatic mutation for NAV2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for NAV2 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg25909885 | chr11:19350465 | CGI:chr11:19346350-19346687 | promoter | 8.30e-01 | 7.02e-01 | 4.43e+00 | 9.37e-06 | 2.56e-05 | 1.28e-01 |
| LUAD | cg06777812 | chr11:19350253 | CGI:chr11:19346350-19346687 | promoter | 7.42e-01 | 8.42e-01 | -3.92e+00 | 8.96e-05 | 2.57e-04 | -1.01e-01 |
| LUAD | cg22946460 | chr11:19350735 | CGI:chr11:19346350-19346687 | UTR,promoter,exon,gene body | 7.54e-01 | 8.77e-01 | -2.90e+00 | 3.69e-03 | 5.82e-03 | -1.23e-01 |
| LUAD | cg00748218 | chr11:19351006 | CGI:chr11:19346350-19346687 | promoter,exon,CDS,gene body | 5.51e-01 | 6.90e-01 | -4.62e+00 | 3.81e-06 | 1.94e-05 | -1.38e-01 |
| LUSC | cg06777812 | chr11:19350253 | CGI:chr11:19346350-19346687 | promoter | 6.91e-01 | 8.58e-01 | -3.82e+00 | 1.33e-04 | 7.94e-04 | -1.67e-01 |
| LUSC | cg23330281 | chr11:19350687 | CGI:chr11:19346350-19346687 | promoter | 5.60e-01 | 8.82e-01 | -3.41e+00 | 6.38e-04 | 1.94e-03 | -3.22e-01 |
| LUSC | cg22946460 | chr11:19350735 | CGI:chr11:19346350-19346687 | UTR,promoter,exon,gene body | 7.10e-01 | 8.89e-01 | -3.11e+00 | 1.88e-03 | 4.00e-03 | -1.79e-01 |
| LUSC | cg06551996 | chr11:19350845 | CGI:chr11:19346350-19346687 | UTR,promoter,exon,gene body | 6.86e-01 | 8.62e-01 | -4.03e+00 | 5.64e-05 | 5.75e-04 | -1.76e-01 |
| LUSC | cg00748218 | chr11:19351006 | CGI:chr11:19346350-19346687 | promoter,exon,CDS,gene body | 5.13e-01 | 6.73e-01 | -3.50e+00 | 4.66e-04 | 1.59e-03 | -1.60e-01 |
| BLCA | cg06777812 | chr11:19350253 | CGI:chr11:19346350-19346687 | promoter | 7.25e-01 | 8.33e-01 | -2.88e+00 | 4.00e-03 | 6.82e-03 | -1.08e-01 |
| BLCA | cg23330281 | chr11:19350687 | CGI:chr11:19346350-19346687 | promoter | 6.01e-01 | 8.72e-01 | -3.31e+00 | 9.33e-04 | 2.15e-03 | -2.70e-01 |
| LIHC | cg22946460 | chr11:19350735 | CGI:chr11:19346350-19346687 | UTR,promoter,exon,gene body | 8.29e-01 | 9.36e-01 | -5.76e+00 | 8.48e-09 | 6.96e-08 | -1.07e-01 |
| ESCA | cg22946460 | chr11:19350735 | CGI:chr11:19346350-19346687 | UTR,promoter,exon,gene body | 6.92e-01 | 8.81e-01 | -2.81e+00 | 4.96e-03 | 3.43e-02 | -1.89e-01 |
| ESCA | cg06551996 | chr11:19350845 | CGI:chr11:19346350-19346687 | UTR,promoter,exon,gene body | 7.21e-01 | 8.30e-01 | -2.04e+00 | 4.18e-02 | 4.72e-02 | -1.10e-01 |
| ESCA | cg00748218 | chr11:19351006 | CGI:chr11:19346350-19346687 | promoter,exon,CDS,gene body | 5.43e-01 | 6.69e-01 | -2.08e+00 | 3.71e-02 | 4.58e-02 | -1.25e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg06777812 | chr11:19350253 | CGI:chr11:19346350-19346687 | promoter | 6.83e-01 | 7.93e-01 | -5.50e+00 | 3.87e-08 | 8.20e-08 | -1.09e-01 |
| BRCA | cg23330281 | chr11:19350687 | CGI:chr11:19346350-19346687 | promoter | 4.85e-01 | 7.49e-01 | -8.79e+00 | 1.54e-18 | 7.38e-18 | -2.64e-01 |
| BRCA | cg22946460 | chr11:19350735 | CGI:chr11:19346350-19346687 | UTR,promoter,exon,gene body | 6.08e-01 | 7.73e-01 | -7.12e+00 | 1.05e-12 | 3.21e-12 | -1.65e-01 |
Top |
Exon skipping events with PSI in TCGA for NAV2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for NAV2 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for NAV2 |
| TFs related to NAV2. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| UVM | ZNF418 | NAV2 | 3.24e+00 | 2.80e-03 | 5.16e+00 | 9.92e-01 | Female-biased |
| NAV2 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for NAV2 |
| RBPs related to ES in NAV2. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| ESCA | ANKHD1 | exon_skip_57438 | 1.18e+01 | 3.69e-03 | 1.24e+01 | 9.96e-01 | Female-biased |
| NAV2 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000166833 | HCCAT5,hsa-mir-130b,NAV2 | Male-specific ceRNA | TCGA-KIRP |
| ENSG00000166833 | AC040174.1,hsa-mir-130b,NAV2 | Male-specific ceRNA | TCGA-KIRP |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs4370915 | chr11:12643451:C:T | - | 0.0481881150427681 | 0.0193060969924499 | LUAD | Female-baised eQTL |
| rs11023872 | chr11:16213027:C:A | - | 0.0778250667812165 | 0.0424639849095978 | LUAD | Female-baised eQTL |
| rs11023876 | chr11:16218565:T:A | - | 0.0778250667812165 | 0.0424639849095978 | LUAD | Female-baised eQTL |
| rs11024719 | chr11:18575765:G:A | - | 0.0904738347465232 | 1.89694909707513e-05 | COAD | Female-baised eQTL |
| rs1838055 | chr11:19849684:G:C | gene | 0.0703396231401022 | 0.002478239821661 | COAD | Female-baised eQTL |
| rs11025290 | chr11:19852873:T:A | gene | 0.0645203361839013 | 0.00261062898611629 | COAD | Female-baised eQTL |
| rs12361438 | chr11:19850359:A:G | gene | 0.0643112071504932 | 0.003009770763248 | COAD | Female-baised eQTL |
| rs2165802 | chr11:19849766:T:C | gene | 0.0626948766942306 | 0.00885792342886087 | COAD | Female-baised eQTL |
| rs57596013 | chr11:21629474:A:G | - | 0.0578869363268885 | 0.0399677071976442 | COAD | Female-baised eQTL |
| rs59865804 | chr11:21629614:C:T | - | 0.0578869363268885 | 0.0399677071976442 | COAD | Female-baised eQTL |
| rs10831781 | chr11:12303149:C:T | - | 0.0628903851925708 | 0.0496407329524349 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs74342571 | chr11:25164292:C:T | - | 0.265998780078141 | 0.017626555489836 | THCA | Male-baised eQTL |
| rs7120514 | chr11:23499945:G:A | - | 0.0790339019534784 | 0.0355418941286803 | STAD | Male-baised eQTL |
| rs2055015 | chr11:29093569:C:A | - | 0.0570281019215467 | 0.0389901943972186 | KIRC | Male-baised eQTL |
| rs74651434 | chr11:25955623:G:A | - | 0.0958936182108663 | 0.00026193252715898 | LUAD | Male-baised eQTL |
| rs12273555 | chr11:25956070:C:A | - | 0.0958936182108663 | 0.00026193252715898 | LUAD | Male-baised eQTL |
| rs12280607 | chr11:25956172:T:C | - | 0.0955284893354798 | 0.000292307607641128 | LUAD | Male-baised eQTL |
| rs2008347 | chr11:25954612:G:A | - | 0.0932182203436348 | 0.000697872368795166 | LUAD | Male-baised eQTL |
| rs4923321 | chr11:25907638:A:T | - | -0.0703320762464492 | 0.00802621361433801 | LUAD | Male-baised eQTL |
| rs7121400 | chr11:20852892:C:T | - | 0.0586974557934581 | 0.0110712185653797 | LUAD | Male-baised eQTL |
| rs4267049 | chr11:19114257:A:G | - | -0.0919743381093956 | 0.0221961669528696 | LUAD | Male-baised eQTL |
| rs1544973 | chr11:20846286:T:C | - | 0.0608230869558011 | 0.029821938693942 | LUAD | Male-baised eQTL |
| rs1838078 | chr11:25609312:A:T | - | -0.072722414274337 | 0.0112270683592432 | COAD | Male-baised eQTL |
| rs1584037 | chr11:25610769:G:C | - | -0.0758279673398494 | 0.0116540041535863 | COAD | Male-baised eQTL |
| rs1443161 | chr11:25609120:T:C | - | -0.0722224515683501 | 0.0127632286060447 | COAD | Male-baised eQTL |
| rs1813996 | chr11:25607617:G:A | - | -0.0726530549462712 | 0.013698314917507 | COAD | Male-baised eQTL |
| rs10742103 | chr11:25606600:G:C | - | -0.0767516969903247 | 0.0141306884464553 | COAD | Male-baised eQTL |
| rs6484154 | chr11:25608294:G:C | - | -0.0692616450516182 | 0.0187964192652945 | COAD | Male-baised eQTL |
| rs1443160 | chr11:25608819:T:C | - | -0.0692616450516182 | 0.0187964192652945 | COAD | Male-baised eQTL |
| rs1443162 | chr11:25609139:A:T | - | -0.0692616450516182 | 0.0187964192652945 | COAD | Male-baised eQTL |
| rs10834713 | chr11:25609567:A:G | - | -0.0692616450516182 | 0.0187964192652945 | COAD | Male-baised eQTL |
| rs10767412 | chr11:25609903:C:A | - | -0.0692616450516182 | 0.0187964192652945 | COAD | Male-baised eQTL |
| rs10767413 | chr11:25610026:A:G | - | -0.0692616450516182 | 0.0187964192652945 | COAD | Male-baised eQTL |
| rs1822357 | chr11:25610699:T:C | - | -0.0692616450516182 | 0.0187964192652945 | COAD | Male-baised eQTL |
| rs326783 | chr11:29611696:A:T | - | 0.051694101120224 | 0.0212822778669497 | COAD | Male-baised eQTL |
| rs1822358 | chr11:25610868:G:A | - | -0.0686174322682348 | 0.0215906508724536 | COAD | Male-baised eQTL |
| rs7946924 | chr11:25604622:T:A | - | -0.0697473488030312 | 0.022596640819914 | COAD | Male-baised eQTL |
| rs10834712 | chr11:25604908:A:G | - | -0.0697473488030312 | 0.022596640819914 | COAD | Male-baised eQTL |
| rs10734362 | chr11:25605816:T:C | - | -0.0697473488030312 | 0.022596640819914 | COAD | Male-baised eQTL |
| rs10767410 | chr11:25606312:T:C | - | -0.0697473488030312 | 0.022596640819914 | COAD | Male-baised eQTL |
| rs10767411 | chr11:25606460:G:A | - | -0.0697473488030312 | 0.022596640819914 | COAD | Male-baised eQTL |
| rs1511516 | chr11:29553830:T:C | - | 0.0482396524392689 | 0.0392286522490862 | COAD | Male-baised eQTL |
| rs4397801 | chr11:25603278:C:T | - | -0.0635494866087546 | 0.0481764527686687 | COAD | Male-baised eQTL |
| rs326779 | chr11:29596312:A:G | - | 0.0452891496335441 | 0.0494454042424898 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000166833 |
| CpG Site: cg20949700 | |
| Position to Gene: gene,exon,UTR | |
| Male Effect: -0.143327244556388 | |
| Female Effect: - | |
 | Gene ID: ENSG00000166833 |
| CpG Site: cg26869615 | |
| Position to Gene: gene,exon,UTR | |
| Male Effect: -0.215750524205952 | |
| Female Effect: - | |
 | Gene ID: ENSG00000166833 |
| CpG Site: cg06777812 | |
| Position to Gene: promoter | |
| Male Effect: -0.341361610887868 | |
| Female Effect: - | |
 | Gene ID: ENSG00000166833 |
| CpG Site: cg05946942 | |
| Position to Gene: gene | |
| Male Effect: -0.341361610887868 | |
| Female Effect: - | |
 | Gene ID: ENSG00000166833 |
| CpG Site: cg12361088 | |
| Position to Gene: gene | |
| Male Effect: -0.341361610887868 | |
| Female Effect: - | |
 | Gene ID: ENSG00000166833 |
| CpG Site: cg19838963 | |
| Position to Gene: gene | |
| Male Effect: -0.341361610887868 | |
| Female Effect: - | |
 | Gene ID: ENSG00000166833 |
| CpG Site: cg19141316 | |
| Position to Gene: gene | |
| Male Effect: -0.341361610887868 | |
| Female Effect: - | |
 | Gene ID: ENSG00000166833 |
| CpG Site: cg22701534 | |
| Position to Gene: gene | |
| Male Effect: -0.341302602594085 | |
| Female Effect: - | |
 | Gene ID: ENSG00000166833 |
| CpG Site: cg04304048 | |
| Position to Gene: gene | |
| Male Effect: -0.341147210335241 | |
| Female Effect: - | |
 | Gene ID: ENSG00000166833 |
| CpG Site: cg06980150 | |
| Position to Gene: gene | |
| Male Effect: -0.340818268512349 | |
| Female Effect: - | |
 | Gene ID: ENSG00000166833 |
| CpG Site: cg21848671 | |
| Position to Gene: gene | |
| Male Effect: -0.338060587466126 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg20949700 | chr11:20022922 | gene,exon,UTR | -0.143327244556388 | 4.70466957144761e-07 | -0.41121560569294857 | 6.6886782925132755e-09 | STAD |
| cg26869615 | chr11:20023093 | gene,exon,UTR | -0.215750524205952 | 3.11977833906564e-06 | -0.37696204060535776 | 7.749827486349567e-09 | STAD |
| cg06777812 | chr11:19350253 | promoter | -0.341361610887868 | 3.0655559704591e-07 | -0.3521080433656915 | 1.7779552288007237e-09 | LUSC |
| cg05946942 | chr11:19540250 | gene | -0.341361610887868 | 3.0655559704591e-07 | -0.3521080433656915 | 1.7779552288007237e-09 | LUSC |
| cg12361088 | chr11:19674142 | gene | -0.341361610887868 | 3.0655559704591e-07 | -0.3521080433656915 | 1.7779552288007237e-09 | LUSC |
| cg19838963 | chr11:19715805 | gene | -0.341361610887868 | 3.0655559704591e-07 | -0.3521080433656915 | 1.7779552288007237e-09 | LUSC |
| cg19141316 | chr11:19728663 | gene | -0.341361610887868 | 3.0655559704591e-07 | -0.3521080433656915 | 1.7779552288007237e-09 | LUSC |
| cg22701534 | chr11:19913612 | gene | -0.341302602594085 | 3.08823075260776e-07 | -0.35217061950510137 | 1.8895774651253214e-09 | LUSC |
| cg04304048 | chr11:19682423 | gene | -0.341147210335241 | 3.13916389794803e-07 | -0.35231513059011893 | 1.9899587034925696e-09 | LUSC |
| cg06980150 | chr11:19710328 | gene | -0.340818268512349 | 3.25352933422262e-07 | -0.35264703485119453 | 2.1972371063177847e-09 | LUSC |
| cg21848671 | chr11:19374119 | gene | -0.338060587466126 | 4.44349110591238e-07 | -0.35881428810327753 | 3.0638847331518824e-08 | LUSC |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| exon_skip_57432 | chr11:20082591:20082600 | In-frame | rs75401693 | chr11:19467804:A:T | Distant upstream | 0.0690666315479437 | 0.00555209690764259 | LUAD | Male-baised sQTL |
| exon_skip_57429 | chr11:20056529:20056628 | In-frame | rs2119981 | chr11:20047418:A:G | Distant upstream | -0.0258884180353193 | 0.0342259479012229 | LGG | Male-baised sQTL |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
 | EX ID: exon_skip_57432 |
| CpG Site: cg02404377 | |
| Position to EX: Distant upstream | |
| Male Effect: - | |
| Female Effect: -0.220305517881928 |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| exon_skip_57432 | chr11:20082591:20082600 | cg02404377 | chr11:20022425 | Distant upstream | -0.220305517881928 | 7.84303996420098e-08 | -0.3118568807312692 | 3.4692789409146993e-06 | In-frame | LUAD |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of NAV2 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000166833 | NAV2 | C0004238 | Atrial Fibrillation | 2 | CTD_human |
| ENSG00000166833 | NAV2 | C0235480 | Paroxysmal atrial fibrillation | 2 | CTD_human |
| ENSG00000166833 | NAV2 | C2585653 | Persistent atrial fibrillation | 2 | CTD_human |
| ENSG00000166833 | NAV2 | C3468561 | familial atrial fibrillation | 2 | CTD_human |
